Custirsen Fails to Improve Survival in Advanced Prostate Cancer Patients

Custirsen Fails to Improve Survival in Advanced Prostate Cancer Patients
The Phase 3 AFFINITY trial failed to met its primary endpoint of significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) being treated with custirsen, the therapy’s maker, OncoGenex, announced. The international, randomized, open-label study evaluated 634 men with CRPC whose disease had progressed despite treatment with docetaxel. In the trial, patients received weekly doses of cabazitaxel or

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *